- Please immediately bring to the attention of all doctors -
Date: 01/05/2018     Contact telephone number: 1300 232 272  (24 hours/7 days)


Management of Gonococcal Infections

Two cases of gonorrhoea with high level resistance to ceftriaxone, azithromycin, ciprofloxacin, penicillin
and tetracycline were diagnosed in Australia in March 2018. One case had recent sex in south east Asia,
the other case had no recent overseas travel so it is likely there are undetected cases. No cases have been
reported in South Australia. Emergence of this gonococcal strain in Australia is of concern, as treatment is
complex and may require intravenous antibiotics.

Initial investigations for suspected gonorrhoea

  • Take a urine or swab for nucleic acid amplification testing (NAAT).
  • Take a swab for culture from any exposed sites (urethra, cervix, pharynx, rectum) in people with symptoms (discharge, dysuria) or recent history of overseas travel.
  • Following a NAAT positive test, take a swab for culture before treatment.
  • Culture of Neisseria gonorrhoeae is critical for detecting antimicrobial resistance.

Treatment of gonorrhoea

  • Unless known to be penicillin allergic, treat uncomplicated genital, ano-rectal or pharyngeal gonococcal infections with:
    ceftriaxone 500mg IM, stat in 2mL 1% lignocaine PLUS azithromycin 1g PO, stat.
  • Do not use ciprofloxacin, penicillin, tetracycline or azithromycin as single agents to treat gonorrhoea.
  • Penicillin allergy is not necessarily a contraindication to ceftriaxone.
  • If penicillin allergic: 
    -  assess allergy as per the antibiotic therapeutic guidelines; 
    -  use ceftriaxone if no history of IgE-mediated immediate allergic reaction (e.g. urticaria, angioedema, bronchospasm or anaphylaxis) or delayed type reactions (e.g. DRESS or SJS/TEN) with penicillin; 
    -  seek specialist advice for patients with immediate type hypersensitivity reactions or delayed type reactions when given penicillin.

Partner notification

  • Stress the importance of partner notification and treating sexual partners.
  • Advise all cases to have no sexual contact for 7 days after treatment is administered.
  • Advise no sex with partners from the last 2 months until the partners have been tested and treated.

Clinical follow-up

  • Clinical follow-up is required for effective management.
  • Review in one week: to assess symptom resolution (if initially symptomatic), to confirm partner notification has occurred and to ensure testing for other STI including HIV and syphilis.
  • Review at 2 weeks after treatment: to undertake test of cure by NAAT and follow-up with culture if NAAT
  • positive.
  • Review at 3 months: to test for re-infection.


  • Notify the Communicable Disease Control Branch (CDCB) on ph: 1300 232 272 or fax: (08) 8226 1800.
  • Immediately advise CDCB by phone of any treatment failures (clinical or culture-proven).

Seek expert advice from Clinic 275, the STI service (8222 5075) about patients with treatment
failure, or who are allergic to ceftriaxone, or with complicated infection, and before using
alternative treatments.

For further details see: Australian National STI guidelines at
Recent public health alerts are available at

Dr Louise Flood – Acting Director, Communicable Disease Control Branch
For updated information on notifiable diseases in South Australia, visit:
Public – I4-A1

Download the official health alert here (PDF)


Beckwith Park, 30 Tanunda Road Nuriootpa SA 5355
PO Box 868 Nuriootpa SA 5355
T 08 8565 8900 F 08 8311 1723
E This email address is being protected from spambots. You need JavaScript enabled to view it.





While the Australian Government Department of Health has contributed to the funding of this website, the information on this website does not necessarily reflect the views of the Australian Government and is not advice that is provided, or information that is endorsed, by the Australian Government. The Australian Government is not responsible in negligence or otherwise for any injury, loss or damage however arising from the use of or reliance on the information provided on this website.

Country SA PHN gratefully acknowledge the financial and other support from the Australian Government Department of Health